ArticleCell death discovery2025

A long noncoding RNA-based serum signature predicts ado-trastuzumab emtansine (T-DM1) treatment benefit in HER2+ metastatic breast cancer patients: a multicenter cohort study.

Syed S Islam et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.